ThermoGenesis Holdings, Inc.
THMO Healthcare Medical Devices
ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022. Operating cash flow growth for three consecutive years.
Follow THMO
ThermoGenesis Holdings, Inc. (THMO) EV/Sales
As of 15 October 2026, ThermoGenesis Holdings, Inc. (THMO) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from 0.0× (May 2016) to 3.6× (May 2020); the current reading is higher than 46% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 0.9× | 35.23% |
| FY2022 | 0.7× | (55.06%) |
| FY2021 | 1.5× | 15.69% |
| FY2020 | 1.3× | 27.49% |
| FY2019 | 1.0× | 165.58% |
| FY2018 | 0.4× | (84.51%) |
| FY2017 | 2.5× | 14.31% |
| FY2017 | 2.2× | (0.66%) |
| FY2016 | 2.2× | 516.56% |
| FY2016 | 0.4× | (81.48%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | 1.1× | 25.76% |
| Dec 2023 | 0.9× | 6.78% |
| Sep 2023 | 0.8× | 2.73% |
| Jun 2023 | 0.8× | 28.96% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFSA PROFUSA, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| FEED ENvue Medical, Inc. compare | 0.1× |
| DYNTQ Dynatronics Corporation compare | 0.1× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| SSKN Strata Skin Sciences, Inc. compare | 0.7× |
| THMO ThermoGenesis Holdings, Inc. | 0.8× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)